According to study details released Friday as the U.S. considers opening vaccinations to that age group, kid-size doses of Pfizer's COVID-19 vaccine appear safe and nearly 91per cent effective at preventing symptomatic infections in 5- to 11-year-olds. The shots could begin in early November — with